MedMira Rapid HIV Test Now Classified as Medical Device in China, Increasing Revenue and Sales Opportunities
The regulatory license for MedMira's rapid HIV test, issued by China's State Food and Drug Administration (SFDA), was successfully renewed and re-classified as part of the ongoing healthcare reforms taking place in the country. As a regulated medical device, MedMira's rapid HIV test can be used in new and growing healthcare sectors including community diagnostic centers and mobile out-reach clinics.
"Similar to the US Food and Drug Administration's medical device regulations, this new classification allows MedMira to overcome a major hurdle in accessing the lucrative
Classified as a drug product by the country's regulators since its initial market entry in 2004, MedMira had experienced a number of complex market barriers in selling its rapid HIV test in large volumes throughout
"We are exploring every sales opportunity for MedMira's rapid HIV test and look forward to increasing sales of this key product in the coming months," said Yiu
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
%SEDAR: 00013053E
For further information: For further information: Andrea Young, (902) 450-1588, [email protected]
Share this article